PDGFRA and cardiomyopathy: We have previously shown that activation of the PDGFRA signaling pathway is a likely pathogenic signaling regulator in the pathogenesis of FLNC-related cardiomyopathy and that treatment with crenolanib, an FDA-approved PDGFRA inhibitor, attenuates the arrhythmic phenotype of FLNCKO hiPSC-CMs [9].